cardiac arrhythmia

Preempting sudden cardiac death

A technique to characterize all variants in genes associated with arrhythmia could improve the ability to identify and preemptively treat individuals at risk for sudden cardiac death.

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Studies by Andrew Glazer, PhD, Giovanni Davogustto, MD, and colleagues found that genetic testing with information from electronic health records can reveal undiagnosed heart rhythm disorders.

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.

VHVI offers latest therapies to treat atrial fibrillation

Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.

Arrhythmia culprit: supertrafficking ion channel

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.

Christopher Ellis, MD, is studying a minimally invasive procedure to treat patients with longstanding atrial fibrillation.

Minimally invasive treatment option for AFib studied

A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.